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Relative amounts of mRNA for cathepsin B were measured in normal murine liver and three murine tumors, an invasive 
liver tumor (hepatoma, Hepa cl 9) and two melanoma variants (B16-Fl and B16 amelanotic melanoma, B16a). Using 
a human cDNA to the cathepsin B coding region as a hybridization probe, we detected two species of cathepsin B specific 
RNA transcripts (2.2 and 4.1 kb) in total RNA preparations of all four tissues. The concentrations of the 2.2 and 4.1 
kb species were 3.6 and 2.7-fold greater in the highly metastatic B16a melanoma than in normal liver. The concentration 
of the 2.2 kb species in the invasive hepatoma was 1.7-fold greater than in normal liver. The increased levels of the 2.2 
kb message were reflected in increases in activity of cathepsin B in both Hepa cl 9 and B16a. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
The cysteine proteinase cathepsin B has been 
hypothesized to play a role in the focal dissolution 
of the extracellular matrix by tumor cells during 
the metastatic ascade. This hypothesis is based in 
part on a correlation between cathepsin B activity 
(in subcutaneous tumors, isolated tumor cells and 
tumor plasma membrane fractions) and the 
metastatic potential of tumor variants (reviews 
[ 1,2]). Enhanced cathepsin B activity in metastatic 
tumors may reflect changes in the concentrations, 
forms or subcellular localization of cathepsin B. 
Here, we have determined whether the enhanced 
cathepsin B activity reflects increased gene expres- 
sion. The levels of cathepsin B-specific RNA 
transcripts in total RNA from liver and three 
tumors were measured in Northern blots using a 
cDNA clone for human cathepsin B [3] as a 
hybridization probe. 
2.1. Tissues 
B16-Fl, B16a and Hepa cl 9 were propagated in their 
syngeneic male hosts, C57BL/6J mice (Jackson Laboratories, 
Bar Harbor, ME) according to our published procedures 141. 
The metastatic (lung colonization) capability of Hepa cl 9 was 
determined and that of the B16 variants verified as in 141. Livers 
were obtained from male C57BL/6J mice without tumors. 
2.2. Isolation of the cDNA clone 
The human cathepsin B cDNA clone, pCB-I was screened 
from a human cDNA library and inserted into the bacterium 
Escherichia cofi as described [3]. A subclone of this plasmid, 
PB-1, containing only the cathepsin B coding region 
(PstIIEcoRI fragment of 593 nucleotides) was selected 13). E. 
co/i harboring the plasmid pB-I was grown in culture according 
to Maniatis et al. 151. The plasmid was amplified in the presence 
of chloramphenicol (Sigma, St. Louis, MO) and purified as 
described in [5]. Plasmid pUCX9 containing cDNA to human 
18 S rRNA [6] was a gift from Dr O.J. Miller (Department of 
Molecular Biology, Wayne State University). 
2.3. RNA isolation 
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A 5 g pool of fresh tissue was minced in homogenization buf- 
fer (4 M guanidine thiocyanate, 0.5% sarkosyl. 25 mM sodium 
acetate, pH 7.0) and homogenized with a Potter-Elvehjem 
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homogenizer (Wheaton Scientific, Millville, NJ) as in 14). Total 
cellular RNA was isolated according to Chomczynski and Sac- 
chi [7], electrophoresed on a 1% agarose-formaldehyde 
denaturing gel (30,xgIlane) according to the procedure of 
Maniatis et al. [S] and transferred to a GeneScreen Plus nylon 
membrane (New England Nuclear, Boston, MA) by electroblot- 
ting (Hoeffer Scientific, San Francisco, CA) or stained with 
ethidium bromide (final concentration 0.5 /g/ml). 
2.4. “P labeling and RNA blot hybridization of the probes 
1 pg of plasmid pB-1 or plasmid pUCX9 was “P labeled by 
nick translation (Bethesda Research Labs, Gaithersburg, MD) 
to a specific activity of 4.0 x 10’ cpm/pg. Alternatively, 60 ng 
of the purified cathepsin B cDNA insert was “P labeled by ran- 
dom priming (Amersham, Arlington Heights, IL) to a specific 
activity of 5.0 x 10s cpm/pg. Nylon membranes were 
prehybridized and then hybridized at 42°C to the radioactive 
probe as described by Maniatis et al. [S]. Washing was done 
twice in 2 x SSC (1 x SSC: 150 mM NaCl, 15 mM sodium 
citrate, pH 7) at room temperature for 5 min, twice in 2 x 
SSC-1% SDS at 60°C for 30 min, and twice in 0.1 x SSC at 
room temperature for 30 min. Autoradiography was performed 
at - 70°C for 30 min to 24 h depending on the intensity of the 
signal. The relative amounts of cathepsin B-specific RNAs were 
quantitated (peak area) by scanning laser densitometry (LKB, 
Bromma, Sweden) of the autoradiograms. 
examined cover a spectrum of metastatic abilities. 
In all three tumors examined cathepsin B activity 
was greater than that in liver. Specific activities 
(determined as I’,,,,,) in liver, Hepa cl 9, B16-Fl 
and B16a homogenates were 5.5, 10.2, 7.7 and 
10.9 nmol/min per mg protein, respectively. The 
proportion of cathepsin B in the plasma membrane 
fraction (L-l) as compared to the lysosomal frac- 
tion (L-2) was greater in the three tumors and this 
elevation was proportional to the metastatic 
capability of all three tumors (fig. l), a finding con- 
sistent with previous studies of both rodent and 
human tumors [1,4,8]. 
2.5. Cathepsin B and protein assays 
Cathepsin B activity (I’,,,,,) in tissue homogenates was deter- 
mined using our published procedure [4]. Subcellular fractiona- 
tions were performed as in [8]. Protein was measured by the 
Bradford procedure 191. 
3. RESULTS 
Based on previous observations of increased 
cathepsin B activity in plasma membrane fractions 
of metastatic tumrs [1,4,8], we chose to examine 
three parameters regarding cathepsin B (activity, 
subcellular localization and mRNA levels) in three 
representative murine tumors and in normal 
murine liver. The three tumors were a hepatoma, 
i.e. a malignant counterpart of the liver, and two 
variants of the B16 melanoma that differ in their 
metastatic capacity (B16-Fl and B16 amelanotic 
melanoma, B16a). The Hepa cl 9 was a locally in- 
vasive tumor with limited metastatic capability, 
forming a median of 2 lung colonies (range, O-6) 
at 21 days post-tail vein injection of 3.75 x lo4 
viable tumor cells into 10 mice. Under the same 
conditions the B16-Fl and B16a form a median of 
25 and 54 lung colonies, respectively [4]. In addi- 
tion, the B16a is reproducibly metastatic after sub- 
cutaneous injection [4]. Thus the three tumors 
Using a human cathepsin B cDNA probe, we 
detected two hybridizable RNA species of 2.2 and 
4.1 kb in the four murine tissues examined (figs 
2,3A). The 4.1 kb transcript can be observed more 
readily in fig.2. The concentration of the 4.1 kb 
transcript (fig.3A) in the two less metastatic 
tumors, Hepa cl 9 and B16-Fl (33 and 33 pg/mg of 
total RNA, respectively), was similar to that in 
liver (26 pg/mg), whereas that in the spontaneous- 
ly metastatic B16a tumor (70 pg/mg) was in- 
creased. In contrast, the concentration of the 
2.2 kb mRNA (fig.3A) was greater in both Hepa cl 
9 and B16a (64 and 150 pg/mg, respectively) than 
in liver (40 pg/mg), yet not in B16-Fl (47 pg/mg). 
This apparent increase in expression of the cathep- 
sin B gene in Hepa cl 9 and B16a was reflected in 
part in increased cathepsin B activity in the respec- 
tive tumors (see above). The amount of RNA per 
lane on the Northern blots was judged to be equal 
by ethidium bromide staining of the ribosomal 
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Fig.1. Ratios of cathepsin B activities in plasma membrane 
(L-l) and lysosomal (L-2) fractions isolated by Percoll density 
gradient centrifugation as described in [S]. 
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Fig.2. (A) Blot hybridization of total RNAs to human cathepsin B cDNA. Lanes: (1,3) liver RNA; (2.4) B16a RNA. Ribosomal RNA 
sizes are indicated in kilobases (kb). (B) Laser densitogram of hybridized mRNAs from A illustrating the absorbance peaks 
corresponding to the 4.1 and 2.2 kb mRNAs in both tissues. (0) B16a, (+) liver. 
bands (not shown) and by hybridization to human 
18 S rRNA-specific cDNA (fig.3B). In addition, 
the amount of hybridizable @actin RNA in the 
tissues showed no correspondence to that of 
cathepsin B-specific RNA transcripts (not shown). 
These data indicate that the increased levels of 
cathepsin B-specific RNA transcripts in Hepa cl 9 
and B16a were specific and not due to differences 
in the amount of total RNA per lane. 
kb 
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4. DISCUSSION 
Indirect evidence had indicated that cathepsin B 
synthesis might be increased in tumors. Koppel et 
al. [lo] had reported that cycloheximide reduces 
the cathepsin B content of a metastatic rat 
anaplastic sarcoma and Recklies et al. [l l] had 
reported that cycloheximide inhibits cathepsin B 
release from malignant human breast tumors. 
1 2 3 4 1 2 3 4 
Fig.3. Blot hybridization of total RNAs to human cathepsin B cDNA (A) and human 18 S rRNA cDNA (B). Lanes 1-4 contain RNA 
from normal mouse liver, B16a, Hepa cl 9 and B16-Fl, respectively. Ribosomal RNA sizes are indicated in kb. 
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Here, we have now provided direct evidence that 
cathepsin B synthesis may be enhanced in two 
tumors. The first of these was a hepatoma that 
arose spontaneously in the liver of C57BL/6J mice 
[12]. Although of low metastatic potential, in our 
hands the Hepa cl 9 was highly invasive, invading 
through the peritoneal wall after subcutaneous im- 
plantation and spreading throughout the 
peritoneal cavity. The second tumor, a melanoma 
(B16a) also syngeneic to C57BL/6J mice, was one 
we have shown to be highly metastatic, both upon 
tail-vein injection and subcutaneous implantation 
[4]. In the third tumor we examined, the B16-Fl, 
a tumor in which we have previously shown a low 
metastatic potential and low cathepsin B activity 
[4,13], the mRNA levels for cathepsin B were not 
greater than in liver. However, the subcellular 
distribution of cathepsin B in this tumor was 
altered so that a significant proportion of cathep- 
sin B was membrane-associated (see fig.1). 
The cathepsin B activity measured in the present 
study in the B16a tumor was similar to that we had 
reported previously [4], i.e. approx. 2-fold greater 
than that in normal liver. The apparent discrepan- 
cy between the levels of the 2.2 kb mRNA 
transcripts (1.7- and 3.6-fold greater in Hepa cl 9 
and B16a than in liver) and cathepsin B activities 
in Hepa cl 9 and B16a may reflect an enhanced 
synthesis of inactive, high-M precursor forms of 
cathepsin B in the B16a tumor and the presence of 
endogenous inhibitors that may affect activity 
measurements. 
Earlier work had identified only one cathepsin 
B-specific transcript of 2.3 kb in nine normal rat 
tissues and one rat tumor [ 141. There has now been 
a report in abstract form of two cathepsin B- 
specific transcripts of 4.0 and 2.2 kb in murine 
melanoma but not in murine liver [ 151. Thus, the 
present study is the first to report two cathepsin B- 
specific transcripts in a normal tissue. 
We have speculated that cathepsin B could be 
one component of a proteolytic cascade that leads 
to the extravasation of metastatic tumor cells [2]. 
Several lines of evidence provide support for this 
hypothesis: (i) the increased activity of cathepsin B 
in metastatic tumors [l]; (ii) an association of 
cathepsin B with plasma membrane fractions of 
metastatic tumors [l] (see also fig.l); and (iii) the 
ability of cathepsin B to degrade components of 
the basement membrane under physiologic condi- 
64 
tions [16]. In the present study we have 
demonstrated that the enhanced cathepsin B activi- 
ty in two tumors reflects an increase in expression 
of the cathepsin B gene. The present study 
therefore suggests that alterations in the expression 
and/or subcellular distribution of cathepsin B in 
tumors may be linked to their invasive and 
metastatic capabilities. 
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